EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Tyk2 Targeting in Immune-Mediated Inflammatory Diseases

Lluís Rusiñol iD, Luis Puig iD

International Journal of Molecular Sciences · 08.02.2023 · 24 (4) · 3391

DOI: 10.3390/ijms24043391 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 08.02.2023. Verfasst von Lluís Rusiñol und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, 08041 Barcelona, Spain. Hauptthemen laut MEDLINE: TYK2 Kinase, Psoriasis. Die Arbeit wurde bisher 81-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Janus kinase (Jak)/signal transducer and activating protein (STAT) pathways mediate the intracellular signaling of cytokines in a wide spectrum of cellular processes. They participate in physiologic and inflammatory cascades and have become a major focus of research, yielding novel therapies for immune-mediated inflammatory diseases (IMID). Genetic linkage has related dysfunction of Tyrosine kinase 2 (Tyk2)—the first member of the Jak family that was described—to protection from psoriasis. Furthermore, Tyk2 dysfunction has been related to IMID prevention, without increasing the risk of serious infections; thus, Tyk2 inhibition has been established as a promising therapeutic target, with multiple Tyk2 inhibitors under development. Most of them are orthosteric inhibitors, impeding adenosine triphosphate (ATP) binding to the JH1 catalytic domain—which is highly conserved across tyrosine kinases—and are not completely selective. Deucravacitinib is an allosteric inhibitor that binds to the pseudokinase JH2 (regulatory) domain of Tyk2; this unique mechanism determines greater selectivity and a reduced risk of adverse events. In September 2022, deucravacitinib became the first Tyk2 inhibitor approved for the treatment of moderate-to-severe psoriasis. A bright future can be expected for Tyk2 inhibitors, with newer drugs and more indications to come.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TYK2 KinasePsoriasisHumansJanus Kinases

Stichwörter der Autor:innen

inflammatory diseasespsoriasistreatment

Substanzen

TYK2 KinaseJanus KinasesTYK2 protein, human

Autor:innen und Institutionen

  • Department of Dermatology IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, 08041 Barcelona, Spain.

ORCID-Profile: Lluís Rusiñol, Luis Puig

Zitieren

APA

Rusiñol, L., & Puig, L. (2023). Tyk2 Targeting in Immune-Mediated Inflammatory Diseases. International Journal of Molecular Sciences, 24(4), 3391. https://doi.org/10.3390/ijms24043391

Vancouver

Rusiñol L, Puig L. Tyk2 Targeting in Immune-Mediated Inflammatory Diseases. International Journal of Molecular Sciences. 2023;24(4):3391. doi:10.3390/ijms24043391

BibTeX
@article{Rusiol2023,
  author = {Rusiñol, Lluís and Puig, Luis},
  title = {Tyk2 Targeting in Immune-Mediated Inflammatory Diseases},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {4},
  pages = {3391},
  doi = {10.3390/ijms24043391}
}
Kostenlos starten →